digital therapeutics

News

Click, Boehringer DTx for schizophrenia passes phase 3 test

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.

News

App to support people with depression launches in GB

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.

News

Digital player Hinge Health rises sharply after NYSE debut

In a signal of a return to investor appetite for digital health stocks, Hinge Health has raised an impressive $437 million in an IPO.

News

Digital therapy for Tourette syndrome backed for NHS use

A digital therapy to reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time.

News

Despite US turmoil, Hinge Health pushes ahead with IPO

Digital health firm Hinge has published a new prospectus for its IPO, shrugging off the weakness in US stock markets caused by Trump's tariffs.

News

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

Click, Boehringer DTx for schizophrenia passes phase 3 test

App to support people with depression launches in GB

Digital player Hinge Health rises sharply after NYSE debut

Digital therapy for Tourette syndrome backed for NHS use

Despite US turmoil, Hinge Health pushes ahead with IPO

FDA clears first migraine DTx from Click Therapeutics

UK first country to launch CSL's trivalent flu shot Aujemflu

Discover a new era of healthcare panel engagement: Grounded ...

digital therapeutics

Editor's Picks